Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bcl‐2 expression

摘要

Summary Aims Retinitis pigmentosa ( RP ) is an inherited disease characterized by a progressive degeneration of rod photoreceptors. An imbalance between pro‐ and antiapoptotic factors, such as Bax/Bcl‐2, has been involved in retinal degeneration. To date, no cure or effective treatments are available for RP . Rasagiline is an antiparkinsonian drug that has shown neuroprotective effects in part attributed to a modulation of Bax/Bcl‐2 expression. In this study, we have evaluated the use of rasagiline as a potential treatment for RP . Methods Newborn rd10 mice, a RP model, were treated with oral rasagiline during 30 days followed by a functional and morphological characterization of their mouse retinas. Results Treated animals showed a significant improvement in visual acuity and in the electrical responses of photoreceptors to light stimuli. Rasagiline delayed photoreceptor degeneration, which was confirmed not only by a high photoreceptor nuclei counting, but also by a sustained expression of photoreceptor‐specific markers. In addition, the expression of proapoptotic Bax decreased, whereas the antiapoptotic factor Bcl‐2 increased after rasagiline treatment. Conclusion This study provides new evidences regarding the neuroprotective effect of rasagiline in the retina, and it brings new insight into the development of future clinical trials using this well‐established antiparkinsonian drug to treat RP .